ImmunityBio Presents Health Economic Analysis at ISPOR 2026 Showing ANKTIVA® Plus BCG Delivers Lower Cost per Sustained Complete Response Versus TAR-200 in BCG-Unresponsive NMIBC CIS
ImmunityBio presented health economic analysis at ISPOR 2026 showing ANKTIVA plus BCG delivers lower cost per sustained complete response versus TAR-200 in BCG-unresponsive NMIBC CIS. The model demonstrated cost savings of $109,622 per cystectomy avoided in Year 1 and $313,775 per complete responder in Year 1 compared to TAR-200.
Key figures
- Response rate tar200
- 45.9%
- Response rate anktiva bcg
- 49.6%
- Cost savings complete responder y1
- 313775
- Cost savings complete responder y2
- 282013
- Cost savings cystectomy avoided y1
- 109622
- Cost savings cystectomy avoided y2
- 151438
- Cost savings cystectomy avoided y3
- 60393
- Cost savings cystectomy free month y1
- 9370
- Cost savings cystectomy free month y2
- 6144
- Cost savings cystectomy free month y3
- 1520
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.